Literature DB >> 6409490

Differences in in vitro binding of diazepam and N-desmethyldiazepam to maternal and fetal plasma proteins at birth: relation to free fatty acid concentration and other parameters.

W Kuhnz, H Nau.   

Abstract

The in vitro protein binding of diazepam and its major plasma metabolite, N-desmethyldiazepam (DMD), was measured in women at full term of pregnancy, in mixed cord plasma (fetal plasma), and in control subjects. The free fraction of both drugs was determined by ultrafiltration at 37 degrees. The mean free fraction of diazepam was 0.023 +/- 0.0043 in control subjects and rose to 0.040 +/- 0.0071 in women at term, whereas in their fetuses the free fraction was 0.021 +/- 0.0057. The unbound fraction of DMD was 0.030 +/- 0.0084 in control subjects, 0.052 +/- 0.015 in women at term, and 0.035 +/- 0.010 in fetal plasma. The free fractions of both compounds differed in women at term and in their fetuses. The higher free fraction of the two drugs in maternal plasma than in cord plasma may be explained by elevated maternal concentrations of free fatty acids (and triglycerides), which may act as displacing agents in maternal plasma. The higher binding of these drugs in fetal plasma than in maternal plasma may explain their cumulation in vivo and may be responsible for the frequently observed adverse effects of maternal diazepam treatment on the newborn infant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409490     DOI: 10.1038/clpt.1983.156

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers.

Authors:  E K Hussey; G E Dukes; J A Messenheimer; K L Brouwer; K H Donn; T F Krol; L J Hak
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

Review 2.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion.

Authors:  Odile Sheehy; Jin-Ping Zhao; Anick Bérard
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

6.  Interaction of diazepam or lorazepam with alcohol. Psychomotor effects and bioassayed serum levels after single and repeated doses.

Authors:  K Aranko; T Seppälä; J Pellinen; M J Mattila
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.

Authors:  H Nau; W Luck; W Kuhnz
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  [Systemic analgesia during labour.].

Authors:  W Klockenbusch; L Beck
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

9.  Species differences in pharmacokinetics and drug teratogenesis.

Authors:  H Nau
Journal:  Environ Health Perspect       Date:  1986-12       Impact factor: 9.031

10.  Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women.

Authors:  Mladena Lalic-Popovic; Jovana Paunkovic; Zorica Grujic; Svetlana Golocorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  BMC Pregnancy Childbirth       Date:  2013-10-17       Impact factor: 3.007

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.